Treatment patterns and outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia: a single center study from Oman - Takeaways - MDSpire

Treatment patterns and outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia: a single center study from Oman

  • By

  • Noor Al-Rawahi

  • Bushra Salman

  • Dhanalekshmi Unnikrishnan Meenakshi

  • Murtadha Al-Khabori

  • Mohammed Al-Hanini

  • Salam Al-Kindi

  • July 15, 2026

Share

  • 1

    The study evaluated treatment patterns and outcomes of tyrosine kinase inhibitors in 112 Omani patients with chronic myeloid leukemia.

  • 2

    First-line imatinib was used in 88.4% of patients, achieving a major molecular response in 51% after a median of 21 months.

  • 3

    Second-line TKIs, nilotinib and dasatinib, showed higher major molecular response rates of 79.2% and 54.4%, respectively.

  • 4

    Treatment-free remission was maintained in 17% of imatinib-treated patients after two years and in 83.3% of second-line patients after 36 months.

  • 5

    Adverse drug reactions were primarily gastrointestinal, musculoskeletal, dermatologic, and hematologic, with 5% experiencing grade 3–4 events.

Original Source(s)

Treatment patterns and outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia: a single center study from Oman

  • by Noor Al-Rawahi, Bushra Salman, Dhanalekshmi Unnikrishnan Meenakshi, Murtadha Al-Khabori, Mohammed Al-Hanini, Salam Al-Kindi

  • July 15, 2026

Related Content

E3 ubiquitin ligase NKLAM/RNF19b suppresses myc-driven B cell lymphomagenesis in Eμ-myc mice

Serum M2BPGi as a predictor of hepatocellular carcinoma development in chronic hepatitis B and C: a systematic review and meta-analysis

Galectins at the crossroads of tumor immunity, metabolism, and metastasis: mechanisms, therapeutic resistance, and translational opportunities